BridgeBio Pharma, Inc DEFA14A, filed Apr 23, 2020

BridgeBio Pharma, Inc. (BBIO)

DEFA14A 2020-04-23

Added on October 16, 2026

☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	(1)	Title of each class of securities to which transaction applies:

	(2)	Aggregate number of securities to which transaction applies:

	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)	Proposed maximum aggregate value of transaction:

	(5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)	Amount previously paid:

	(2)	Form, Schedule or Registration Statement No.:

	(3)	Filing party:

	(4)	Date Filed:

	·	We are delivering our investigational medicines to patients directly now that many can no longer visit the hospital.
	·	We are implementing out-of-hospital solutions for our clinical trials – including telehealth appointments and remote clinical monitoring.
	·	We have engaged in conversations with the FDA across multiple programs to understand how we preserve the fidelity of key endpoints in this era of increased variance.
	·	We are working closely with our contract manufacturing partners to anticipate any potential downstream impacts to our immediate supply chain, and to date there have been none.
	·	We are working on key aspects of site activation and support so that we can continue enrolling patients where and when possible.
	·	We have transferred many of our pre-clinical laboratory activities to contract research organizations that continue to work on them, when we have not been able to sustain them ourselves.
	·	We have shored up our balance sheet with the recent addition of $550 million gross from a seven-year maturity convertible debt offering so that we can continue working to execute on all the programs in our pipeline.

	·	We now have more than 20 drug development and discovery programs in our pipeline, spanning multiple therapeutic areas and drug modalities.
	·	Since the beginning of 2019, we have initiated eight clinical trials, added five new development programs, and filed multiple INDs, along with our first NDA.

	·	In 2020, we expect to file an additional NDA and several more INDs, as well as add more programs to our pipeline.
	·	We have brought two programs from the research lab to the start of Phase 3 clinical trials in less than three years and for less than $50 million each, far better than the industry average. This is the capital-efficient approach we feel is needed to develop treatments for under-served patient populations.

	·	Genetic sequencing: It’s now cheaper and easier than ever to sequence a patient’s exome and genome and to identify causal genetic variants
	·	Big patient data: Advancements in longitudinal patient databases allow us to match disease phenotypes to patient genotypes and understand the quantitative drivers of disease
	·	Molecular biology: We have better tools to assay and maps to understand the molecular systems that tie DNA to protein signaling to cellular and tissue level regulation. These insights reveal the causal chain between gene and symptom that we hope to exploit using our therapeutics

·	Distinctive early-stage asset selection

	o	Our ability to identify and select the most impactful programs to develop from the vast array of opportunities is key to our mission of bringing life-changing therapies to patients. We rely on some of the top R&D minds in the industry for this work, including

		Charles Homcy, M.D., Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) and Richard Scheller, Ph.D.

·	Experienced, world-class R&D team

	o	Our ability to put these programs into the hands of R&D operators who know how to drive towards turning them into actual, useful drugs is critical. Our world-class R&D team is collectively responsible for over 100 INDs and 20-plus approved products and includes scientific leaders like Uma Sinha, Ph.D., Eli Wallace, Ph.D., and Robert Zamboni, Ph.D.

·	Efficient corporate structure

	o	Our lean corporate structure allows us to grow our pipeline and incentivizes us to learn and improve processes

·	The willingness and the scale to fail

	o	Our pipeline is broad, diversified, and uncorrelated, which means we can afford to be sanguine about our programs and advance or discontinue them based upon their scientific merits, with limited risk to the company as a whole

·	Focus at the level of individual diseases and assets

	o	We believe that small, highly skilled teams of experts are more efficient and more productive than larger teams of generalists

	·	You should expect us to put patients first
	·	You should expect us to measure our performance based on our rate of success, the number of programs in our pipeline and our capital efficiency
	·	You should expect our performance to improve over time – we should get even better at drug development by iterating through the process repeatedly
	·	You should expect us to double down on programs on a risk-adjusted basis when we determine them to be promising
	·	You should expect us to discontinue programs that aren’t working and are unlikely to help patients
	·	You should expect us to go into both large and small disease areas – thanks to our capital-efficient and flexible corporate model we believe we can develop actual blockbusters with large patient populations; but we can also be the best owners of programs with smaller addressable populations, several of which together could potentially form a “synthetic blockbuster”
	·	You should expect us to prioritize benefit to patients, including pursuing partnerships when we determine we are not the best owner of a program
	·	You should expect us to pursue M&A opportunities to maximize the potential for future medicines

	·	You should expect us to always seek to be first-in-class or best-in-class – or both
	·	You should expect us to let our science speak and drive our work